Last $190.28 USD
Change Today +0.84 / 0.44%
Volume 778.1K
AGN On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 12:44 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Open
$189.45
Previous Close
$189.44
Day High
$191.40
Day Low
$188.74
52 Week High
10/9/14 - $192.98
52 Week Low
11/7/13 - $88.34
Market Cap
56.5B
Average Volume 10 Days
2.6M
EPS TTM
$5.34
Shares Outstanding
297.2M
EX-Date
11/18/14
P/E TM
35.6x
Dividend
$0.20
Dividend Yield
0.11%
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,500 Employees
Last Reported Date: 10/27/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
President
Total Annual Compensation: $651.9K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Non-Executive Officer
Total Annual Compensation: $641.5K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Allergan Inc. Declares Third Quarter Dividend, Payable on December 11, 2014

Allergan Inc. declared a third quarter dividend of $0.05 per share, payable on December 11, 2014 to stockholders of record on November 20, 2014.

Allergan Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Operating Guidance for the Full Year of 2014 and Earnings Guidance for the Fourth Quarter and Full Year of 2014

Allergan Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues of $1,817.1 million compared to $1,558.7 million a year ago. Operating income was $392.8 million compared to $490.2 million a year ago. Earnings from continuing operations before income taxes were $419.4 million compared to $456.8 million a year ago. Earnings from continuing operations were $313.1 million or $1.03 per diluted share, compared to $332.9 million or $1.10 per diluted share, a year ago. Net earnings attributable to the company were $312.5 million or $1.03 per diluted share, compared to $299.8 million or $1.00 per diluted share, a year ago. Non-GAAP operating income was $725.2 million compared to $531.6 million a year ago. Non-GAAP earnings from continuing operations before income taxes were $717.5 million compared to $505.9 million a year ago. Non-GAAP earnings from continuing operations were $540.0 million or $1.78 per diluted share, compared to $368.8 million or $1.23 per diluted share, a year ago. Non-GAAP net earnings attributable to the company were $312.5 million or $1.03 per diluted share, compared to $299.8 million or $1.00 per diluted share, a year ago. For the year to date, the company reported revenues of $5,327.4 million compared to $4,616.0 million a year ago. Operating income was $1,382.6 million compared to $1,354.5 million a year ago. Earnings from continuing operations before income taxes were $1,355.4 million compared to $1,289.8 million a year ago. Earnings from continuing operations were $990.0 million or $3.25 per diluted share, compared to $959.9 million or $3.17 per diluted share, a year ago. Net earnings attributable to the company were $987.0 million or $3.25 per diluted share, compared to $672.2 million or $2.23 per diluted share, a year ago. Non-GAAP operating income was $1,900.5 million compared to $1,484.7 million a year ago. Non-GAAP earnings from continuing operations before income taxes were $1,852.3 million compared to $1,419.0 million a year ago. Non-GAAP earnings from continuing operations were $1,360.1 million or $4.47 per diluted share, compared to $1,037.8 million or $3.42 per diluted share, a year ago. Non-GAAP net earnings attributable to the company were $1,357.4 million or $4.47 per diluted share, compared to $1,033.6 million or $3.42 per diluted share, a year ago. The company provided operating guidance for the full year of 2014 and earnings guidance for the fourth quarter and full year of 2014. For the full year, the company is expecting its total product net sales between $7,080 million and $7,155 million, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business; total product net sales between $7,080 million and $7,155 million, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business; total specialty pharmaceuticals net sales between $5,990 million and $6,045 million; total core medical devices net sales between $1,050 million and $1,070 million; ALPHAGAN® franchise product net sales between $500 million and $510 million; LUMIGAN® franchise product net sales between $650 million and $670 million; RESTASIS® product net sales between $1,070 million and $1,090 million; BOTOX® product net sales between $2,200 million and $2,240 million; LATISSE® product net sales at approximately $100 million; Breast aesthetics product net sales between $400 million and $410 million; Facial aesthetics product net sales between $650 million and $660 million; non-GAAP diluted earnings per share attributable to stockholders between $6.27 and $6.30; and effective tax rate on non-GAAP earnings at approximately 26%. For the fourth quarter, the company expects its total product net sales between $1,845 million and $1,920 million, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business; and non-GAAP diluted earnings per share attributable to stockholders between $1.80 and $1.83.

Allergan Inc., Q3 2014 Earnings Call, Oct 27, 2014

Allergan Inc., Q3 2014 Earnings Call, Oct 27, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $190.50 USD +1.06

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $243.50 USD +0.29
Astellas Pharma Inc ¥1,699 JPY +61.50
Mylan Inc/PA $53.73 USD +1.36
Regeneron Pharmaceuticals Inc $395.33 USD +2.53
Shire PLC 4,163 GBp -1.00
View Industry Companies
 

Industry Analysis

AGN

Industry Average

Valuation AGN Industry Range
Price/Earnings 43.5x
Price/Sales 7.9x
Price/Book 7.8x
Price/Cash Flow 39.3x
TEV/Sales 7.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit www.allergan.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.